ALXN - Alexion shares rise on Q1 earnings beat

Alexion Pharmaceuticals (ALXN) shares rise more than 2% during premarket trading as the company posted first-quarter results that beat Wall Street estimates.The company's quarterly revenue increased 14% to $1.64B, compared to analyst' estimate of $1.58B.Net product sales were $1,636M in the first quarter of 2021, compared to $1,445M in the same period last year.SOLIRIS net product sales were $1,027.6M, compared to $1,022.9M last year, while ULTOMIRIS net product sales were $346.9M versus $222.8M last year.GAAP R&D expense was $289.1M, compared to $200.9M in the three months ended March 31.The company also posted adjusted quarterly profit of $3.52 per share, beating analysts' estimate by 38 cents.Previously (April 30): Alexion Pharmaceuticals EPS beats by $0.38, beats on revenue.

For further details see:

Alexion shares rise on Q1 earnings beat